SCHEMBL31709902

SCHEMBL31709902

COC(=O)c1ccc(-n2ccc([N+](=O)[O-])n2)cc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 1/20 0.44
F2 P00734 1/20 0.42
PLAU P00749 1/20 0.42
KLKB1 P03952 1/20 0.42
ELANE P08246 1/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MYC P01106 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SIRT6 Q8N6T7 1/20 0.40
PDGFRB P09619 1/20 0.40
FGFR1 P11362 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT1 P17948 1/20 0.40
FGFR3 P22607 1/20 0.40
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31710511 0.83 KMT2A (0.49) KMT2AALDH1A1POLBF2PLAU
SCHEMBL44933 0.80 HTT (0.49) KMT2AALDH1A1F2PLAUKLKB1
SCHEMBL31709884 0.80 ALDH1A1 (0.45) KMT2AALDH1A1POLBKDM4EMAPT
SCHEMBL31316911 0.79 TP53 (0.54) KMT2AALDH1A1F2PLAUKLKB1
SCHEMBL31709751 0.76 F2 (0.38) KMT2AALDH1A1POLBF2PLAU
SCHEMBL31316868 0.75 MAPT (0.51) KMT2AALDH1A1POLBF2PLAU
SCHEMBL31316818 0.73 F2 (0.50) KMT2AALDH1A1F2PLAUKLKB1
SCHEMBL20556372 0.73 MAPT (0.52) KMT2AALDH1A1KDM4EMAPTALOX15
SCHEMBL31316940 0.73 F2 (0.47) KMT2AALDH1A1POLBF2PLAU
SCHEMBL31316910 0.72 F2 (0.50) KMT2AALDH1A1POLBF2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224599-A1 PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-10-30 WO disclosed
US-20250326741-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326741-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF GIPR, GLP1R, GPR119 KMT2A 4154/4885ALDH1A1 2017/4885POLB 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.